(PharmaNewsWire.Com, July 31, 2020 ) The major factors that are expected to be driving the high content screening market are need for cost containment in pharma R&D, growth in funding for cellular research, and technological advancements in HCS solutions are expected to support the growth of the HCS market during the forecast period.
MarketsandMarkets forecasts the high content screening market to grow from USD 557.1 million in 2017 to USD 909.0 million by 2022, at a Compound Annual Growth Rate (CAGR) of 10.3% during the forecast period.
The growth of this market is attributed to the technological advancements in image acquisition, data analysis, and storage capabilities and the need to obtain information on changes in cell morphology through high-quality images.
What Drives the Market?
1. Need for Cost Containment in Pharmaceutical R&D 2. Government Funding and Venture Capital Investments Across Developed Markets 4. Advancements in Informatics Solutions and Imaging Instruments
The HCS instruments market accounted for the largest share of HCS market primarily attributed to advances in instrumentation and automation techniques and high prices of the HCS instruments. The software segment is expected to register the highest growth during the forecast period.
On the basis of application, the high-content screening market is segmented into target identification and validation, primary and secondary screening, toxicity studies, compound profiling, and other applications such as angiogenesis, apoptosis, cell cycle and mitotic index, cell proliferation, endocytosis, protein synthesis, and stem cell differentiation.
The geographical regions mapped in the report are: 1. North America 2. Europe 3. Asia-Pacific 4. Latin America 4. Middle East & Africa
North America is the largest market for high-content screening, followed by Europe, Asia-Pacific, Latin America, and the Middle East & Africa. High R&D expenditure, the presence of major pharmaceutical market players, and increasing government support are some of the factors contributing to the large share of North America in the market.
Some key players mentioned in the research report are:
GE Healthcare (U.S.), Danaher Corporation (U.S.), Thermo Fisher Scientific, Inc. (U.S.), PerkinElmer, Inc. (U.S.), Tecan Group (Switzerland), BioTek Instruments Inc. (U.S.), Becton, Dickinson and Company (U.S.), Bio-Rad Laboratories (U.S.), Yokogawa Electric Corporation (Japan), and Merck Millipore (U.S.)
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including: